These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 11916237

  • 1. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H, Arteaga CL.
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
    Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT, Arteaga CL.
    Cancer Res; 2000 Oct 15; 60(20):5887-94. PubMed ID: 11059787
    [Abstract] [Full Text] [Related]

  • 3. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M, Thottassery JV, Hays S, Qu Z, Rentz SS, Westbrook L, Kern FG.
    Oncogene; 2006 Sep 28; 25(44):6003-14. PubMed ID: 16682955
    [Abstract] [Full Text] [Related]

  • 4. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I, Blackwell K, Chen S, Slingerland J.
    Cancer Res; 2005 Jan 01; 65(1):18-25. PubMed ID: 15665275
    [Abstract] [Full Text] [Related]

  • 5. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.
    Kurokawa H, Arteaga CL.
    Clin Cancer Res; 2003 Jan 01; 9(1 Pt 2):511S-5S. PubMed ID: 12538508
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.
    Cancer Res; 2001 Sep 15; 61(18):6747-54. PubMed ID: 11559546
    [Abstract] [Full Text] [Related]

  • 8. Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.
    Yang X, Yang S, McKimmey C, Liu B, Edgerton SM, Bales W, Archer LT, Thor AD.
    Carcinogenesis; 2010 Apr 15; 31(4):695-702. PubMed ID: 20067990
    [Abstract] [Full Text] [Related]

  • 9. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
    Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.
    Cancer Res; 2006 Aug 15; 66(16):8266-73. PubMed ID: 16912207
    [Abstract] [Full Text] [Related]

  • 10. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.
    Oncogene; 2002 Jun 06; 21(25):4000-8. PubMed ID: 12037682
    [Abstract] [Full Text] [Related]

  • 11. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ, Hilger AM, Murthy S, Rae JM, Chinnaiyan AM, El-Ashry D.
    Cancer Res; 2006 Apr 01; 66(7):3903-11. PubMed ID: 16585219
    [Abstract] [Full Text] [Related]

  • 12. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
    Kinoshita Y, Chen S.
    Cancer Res; 2003 Jul 01; 63(13):3546-55. PubMed ID: 12839940
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tea polyphenol (-)-epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling.
    Pan MH, Lin CC, Lin JK, Chen WJ.
    J Agric Food Chem; 2007 Jun 27; 55(13):5030-7. PubMed ID: 17539658
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
    Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK.
    Cancer Chemother Pharmacol; 2005 Nov 27; 56 Suppl 1():10-20. PubMed ID: 16273359
    [Abstract] [Full Text] [Related]

  • 18. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.
    Cancer Res; 2003 Feb 01; 63(3):627-35. PubMed ID: 12566306
    [Abstract] [Full Text] [Related]

  • 19. Co-expressed type of ER and HER2 protein as a predictive factor in determining resistance to antiestrogen therapy in patients with ER-positive and HER2-positive breast cancer.
    Horiguchi J, Koibuchi Y, Iijima K, Yoshida T, Takata D, Rokutanda N, Nagaoka R, Oyama T, Iino Y, Morishita Y.
    Oncol Rep; 2005 Nov 01; 14(5):1109-16. PubMed ID: 16211272
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.